Caris to provide DNA and RNA molecular testing to support patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial UTRECHT, The Netherlands and CAMBRIDGE, Mass. and IRVING, ...

Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for ...

Sanofi’s immuno-oncology program leader Appoints Andrew Joe, M.D., has jumped ship from the French Big Pharma to Netherlands-based biotech Merus. He becomes it new chief medical officer, overseeing ...

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction ...

Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, entered into an agreement in which Merus has exclusively licensed to Partner ...

Denmark’s Genmab A/S agreed to acquire Merus NV, a Dutch biotechnology company that’s developing a treatment for cancer of the head and neck, for about $8 billion. Genmab will buy Merus shares at $97 ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other ...